Innovative Strategies for Overcoming Resistance in Tumor Angiogenesis Therapies

3,053
Total downloads
13k
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 08 Oct 2025

Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients

Lingli Lei
Xiang Zhan
Jixian Li
Yi Ding
Jiaxin Li
Fengge Zhou
Alei Feng
Xiaomei Li
Zhe Yang

doi 10.3389/fphar.2025.1503171

673 views

ORIGINAL RESEARCH

Published on 12 Aug 2025

KCTD10 inhibits lung cancer metastasis and angiogenesis via ubiquitin-mediated β-catenin degradation

Zihao Yin
Shengwen Long
Hao Zhou
Mi Ouyang
Qinghao Wang
Jun He
Rongyu Su
Zhiwei Li
Xiaofeng Ding
Shuanglin Xiang

doi 10.3389/fimmu.2025.1630311

1,816 views
1 citation

SYSTEMATIC REVIEW

Published on 25 Jul 2025

Vasculogenic mimicry in non-small cell lung cancer: a systematic review

Valeriia Shapkina
Vadim Shindyapin
Nikita Burlov
Elizaveta Prosekina
Anna Artemyeva

doi 10.3389/fonc.2025.1481726

1,398 views

ORIGINAL RESEARCH

Published on 23 Jul 2025

Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation

Qiong Zhou
Rui Wang

doi 10.3389/fphar.2025.1581820

1,539 views

SYSTEMATIC REVIEW

Published on 30 May 2025

Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis

Yijun Wang
Yicong Wang
Lei Wang
He Yuan
Yongai Yu
Daju Liu

doi 10.3389/fphar.2025.1566604

1,500 views

SYSTEMATIC REVIEW

Published on 21 Nov 2024

Efficacy and safety of anti-angiogenic drugs combined with chemotherapy in the treatment of platinum-sensitive/resistant ovarian cancer: a meta-analysis with trial sequential analysis of randomized controlled trials

Haining He
Fei Zhou

doi 10.3389/fphar.2024.1446403

1,420 views

ORIGINAL RESEARCH

Published on 24 Jun 2024

A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC

Tian Xing
Qianqian Gao
Hongbin Zhu
Jianrong Gao
Ganglin Yan

doi 10.3389/fimmu.2024.1402018

1,252 views

Share on

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs
Translational Pharmacology
Ethnopharmacology

Participating Journals

Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- 3.3 impact factor
- 6.9 citescore

Impact

13kTopic views
9,051Article views
3,053Article downloads

View impact

Articles

Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients

KCTD10 inhibits lung cancer metastasis and angiogenesis via ubiquitin-mediated β-catenin degradation

Vasculogenic mimicry in non-small cell lung cancer: a systematic review

Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation

Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis

Efficacy and safety of anti-angiogenic drugs combined with chemotherapy in the treatment of platinum-sensitive/resistant ovarian cancer: a meta-analysis with trial sequential analysis of randomized controlled trials

A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Translational Pharmacology

Ethnopharmacology

Participating Journals

Frontiers in Oncology

Pharmacology of Anti-Cancer Drugs